Dipeptidyl peptidase-4 (DPP-4) degrades circulating GLP-1 and GIP and reduces the circulating postprandial glucagon level [4]; hence, DPP4 inhibitors are regarded as a novel means for extending the action of insulin and treating T2DM. Here, GCG is linked to type 2 diabetes mellitus.